Compare FLY & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLY | HALO |
|---|---|---|
| Founded | 2017 | 1998 |
| Country | United States | United States |
| Employees | 1409 | N/A |
| Industry | Military/Government/Technical | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9B | 8.8B |
| IPO Year | N/A | 2001 |
| Metric | FLY | HALO |
|---|---|---|
| Price | $38.25 | $69.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 11 |
| Target Price | $38.88 | ★ $78.64 |
| AVG Volume (30 Days) | ★ 8.3M | 1.7M |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.22 |
| Revenue | N/A | ★ $151,862,000.00 |
| Revenue This Year | $174.79 | $28.24 |
| Revenue Next Year | $66.73 | $12.56 |
| P/E Ratio | ★ N/A | $57.23 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.00 | $51.06 |
| 52 Week High | $62.17 | $82.22 |
| Indicator | FLY | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 46.30 | 59.01 |
| Support Level | $18.95 | $67.94 |
| Resistance Level | $48.28 | $70.93 |
| Average True Range (ATR) | 5.11 | 2.07 |
| MACD | -1.16 | 0.10 |
| Stochastic Oscillator | 8.35 | 90.84 |
Firefly Aerospace Inc is a space and defense technology company with an established track record of success providing comprehensive mission solutions to national security, government, and commercial customers. The company develops and provides space and defense technologies, including launch vehicles and spacecraft systems, supporting launch, transit, and in-orbit operations for government, commercial, and national security customers. It has only one operating segment. The majority of the company's revenue is derived from Spacecraft Solutions.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.